MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy

• Published in: European radiology Vol. 22; no. 2; pp. 341 - 349
• Main Authors: Meeuwis, Carla, Veltman, Jeroen, van Hall, Hester N., Mus, Roel D. M., Boetes, Carla, Barentsz, Jelle O., Mann, Ritse M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.02.2012; Springer Nature B.V
• Subjects: Adult; Aged; Biopsy; Biopsy - methods; Biopsy, Needle - methods; Breast; Breast - pathology; Breast cancer; Clinical medicine; Diagnostic Radiology; Equipment Design; Female; Humans; Imaging; Internal Medicine; Interventional Radiology; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Magnetic Resonance Imaging, Interventional - methods; Mass Screening - methods; Medicine; Medicine & Public Health; Middle Aged; Morphology; Neuroradiology; Radiology; Radiology - methods; Reproducibility of Results; Treatment Outcome; Ultrasonic imaging; Ultrasound; Vacuum; Netherlands; Germany; High field; Breast cancer; Biopsy; MRI; Neoplasms
• ISSN: 0938-7994; 1432-1084
• DOI: 10.1007/s00330-011-2272-6

Objective The purpose of this study was to evaluate two MR-guided biopsy techniques at 3 T, large core needle breast biopsy (LCNB) and vacuum-assisted breast biopsy (VAB) and to compare the diagnostic yield and rate of complications to determine the optimal biopsy technique at 3 T. Methods 55 LCNB and 64 VAB were consecutively performed. Benign biopsy results were verified by retrospective correlation of histology, with pre-interventional, post-interventional MRI studies and follow-up and were classified as representative or non-representative. Time to follow-up was up to 2 years for the considered non-representative benign lesions. Statistical analysis was performed using the Chi-squared test. Results LCNB was technically successful in 100% of patients (55/55) and VAB in 98% of patients (63/64). Histopathological analysis resulted in 45 (82%) benign, 3 (5%) high-risk and 7 (13%) malignant lesions for LCNB and 43 (67%) benign, 3 (5%) high-risk and 18 (28%) malignant lesions. Distribution was significantly different ( p  < 0.001), favouring VAB over LCNB. Conclusion Because of the substantially higher diagnostic yield and certainty of a benign diagnosis, VAB is the optimal biopsy technique at 3 T. LCNB should be considered when VAB is not feasible.